02:41 AM EDT, 09/01/2026 (MT Newswires) -- GSK (GSK.L) said Tuesday it intends to launch a phase 3 efficacy trial for its messenger ribonucleic acid, or mRNA, seasonal influenza vaccine candidate in September after reporting positive phase 2 data. In the phase 2 Flu-028 trial, the vaccine candidate demonstrated stronger immune responses against all tested influenza strains, compared with licensed standard-dose flu vaccines in younger adults and high-dose flu vaccines in older adults. The randomized, observer-blind Flu-028 study enrolled 971 adults aged 18 years and older, who received varying doses of GSK's multivalent seasonal flu vaccine candidates.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.